Clinical trial · Interventional
CD70-targeted immunoPET Imaging of Malignant Cancers
CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
NCT06852638CI-TRIAL-00111149recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Follicular Lymphoma | Follicular Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphoma, Large B-Cell, Diffuse | Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Renal Cancer | — | UNRESOLVED | — |
| Renal Clear Cell Carcinoma | Clear Cell Renal Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]F-RESCA-R8B4 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-RCCB6 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-RD06 | Drug | — | UNRESOLVED |
| [68Ga]Ga-NOTA-R8B4 | Drug | — | UNRESOLVED |
| [68Ga]Ga-NOTA-RD06 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CD70-targeted immunoPET imaging
- description
- Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.
- interventionNames
- Drug: [18F]F-RESCA-RCCB6
- Drug: [18F]F-RESCA-R8B4
- Drug: [68Ga]Ga-NOTA-R8B4
- Drug: [18F]F-RESCA-RD06
- Drug: [68Ga]Ga-NOTA-RD06
Primary outcomes (2)
- measure
- The uptake patterns of CD70-targeted tracers across different tumors
- timeFrame
- One month after the injection of the tracers
- description
- Because the expression level of CD70 varies across tumors, including renal cell carcinoma (especially clear cell renal cell carcinoma), nasopharyngeal carcinoma, and lymphoma, due to different regulatory pathways, this variation will lead to differential uptake of CD70 tracers in these tumors. Therefore, the primary goal of the prospective study is to determine the uptake and distribution patterns of CD70-targeted tracers in patients with renal cell carcinoma (particularly clear cell), nasopharyngeal carcinoma, or lymphoma. To achieve this, imaging tracer uptake in tumors and normal organs/tissues will be scored both visually and quantitatively. Uptake will be correlated with CD70 expression determined by immunohistochemical staining.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18-80 year-old and of either sex； * Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; * Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol. Exclusion Criteria: * Pregnancy； * Severe hepatic and renal insufficiency; * Allergic to single-domain antibody radiopharmaceuticals.
References
Publications (0)
Data not yet available
No reference posted for this study.